Orexo eyes real-world testing of its modia opioid use disorder appOrexo will start a new study of its modia app – used to treat people with opioid use Share XOrexo eyes real-world testing of its modia opioid use disorder apphttps://pharmaphorum.com/news/orexo-eyes-real-world-testing-of-its-modia-opioid-use-disorder-app/
Digital therapies for opioid use disorder need more data, says ICERThere isn’t enough evidence to suggest that digital therapies for people with opioid use disorder (OUD) can improve Share XDigital therapies for opioid use disorder need more data, says ICERhttps://pharmaphorum.com/news/digital-therapies-for-opioid-use-disorder-need-more-data-says-icer/
Purdue to pay $8.3bn after admitting criminal charges in opioid caseAfter years of legal wrangling, Purdue Pharma has agreed a deal to resolve litigation about its role in Share XPurdue to pay $8.3bn after admitting criminal charges in opioid casehttps://pharmaphorum.com/news/purdue-to-pay-8-3bn-after-admitting-criminal-charges-in-opioid-case/
Orexo eyes opioid use disorder app launch before year-endSweden’s Orexo says its opioid use disorder (OUD) digital therapeutic – now christened Modia – is on course Share XOrexo eyes opioid use disorder app launch before year-endhttps://pharmaphorum.com/news/orexo-eyes-opioid-use-disorder-app-launch-before-year-end/
After final $600M opioid settlement, Indivior looks to the futureUK drugmaker Indivior looks finally to have put years of uncertainty over its exposure to opioid litigation in Share XAfter final $600M opioid settlement, Indivior looks to the futurehttps://pharmaphorum.com/news/after-final-600m-opioid-settlement-indivior-looks-to-the-future/
Mallinckrodt proposes $1.6bn deal to settle opioid litigationMallinckrodt is placing a $1.6 billion settlement package on the table as it tries to bring litigation related Share XMallinckrodt proposes $1.6bn deal to settle opioid litigationhttps://pharmaphorum.com/news/mallinckrodt-proposes-1-6bn-deal-to-settle-opioid-litigation/
FDA rejects Adamis opioid overdose therapy Zimhi, hitting share priceShares in Adamis Pharmaceuticals have been poleaxed by an FDA decision to reject Zimhi, intended as a treatment Share XFDA rejects Adamis opioid overdose therapy Zimhi, hitting share pricehttps://pharmaphorum.com/news/fda-rejects-adamis-opioid-overdose-therapy-zimhi-hitting-share-price/
Federal opioid trial averted by last-ditch settlementTeva and three pharma wholesalers have agreed a $260 million settlement with two Ohio counties over their role Share XFederal opioid trial averted by last-ditch settlementhttps://pharmaphorum.com/news/federal-opioid-trial-averted-by-last-ditch-settlement/
Is the US opioid litigation nearing an end game?Drugmakers, wholesalers and lawmakers in the US are said to be thrashing out the details of a big Share XIs the US opioid litigation nearing an end game?https://pharmaphorum.com/news/is-the-us-opioid-litigation-nearing-an-end-game/
